Forward Therapeutics
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $50M
Overview
Developing oral small molecule immunology drugs targeting novel inflammatory pathways.
Immunology
Technology Platform
A chemistry and structural biology platform focused on designing selective oral small molecules against novel intracellular targets in immune cell signaling pathways.
Funding History
1Total raised:$50M
Series A$50M
Opportunities
Potential for oral therapies that offer comparable efficacy to biologics with greater patient convenience and potentially lower cost.
Risk Factors
High risk of preclinical failure and difficulty demonstrating superiority or non-inferiority to highly effective, established biologic therapies.
Competitive Landscape
Enters a highly competitive immunology market dominated by biologics, requiring clear differentiation in safety, efficacy, or convenience to succeed.